The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | The role of bispecific antibodies in the treatment of patients with multiple myeloma
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, Miami, FL, gives an overview of the role of bispecific antibodies in the treatment of multiple myeloma (MM). In the past few years, three bispecifics have been approved for MM. They target BCMA or GPRC5D, which are expressed on the surface of myeloma cells, and CD3, which is expressed on T-cells. Currently, these agents are approved for patients with four or more prior lines of therapies, but studies are investigating how they could be used in earlier lines as well as in newly diagnosed patients. Dr Landgren highlights that bispecifics will change the field of MM for the better. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex; Honoraria: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex; Membership on an entity’s Board of Directors or advisory committees: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex; Membership on independent data monitoring committees: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex.
